The effects of zopiclone on obstructive sleep apnoea

The effects of zopiclone on obstructive sleep apnoea severity and symptoms of daytime sleepiness and measures of alertness

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12613001106729

Acronym

ZOPOSA

Enrollment

Registered

2013-10-03

Start date

2013-10-09

Completion date

2016-02-02

Last updated

2022-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The purpose of this study is to examine the effects of nightly administration of a standard dose of a common sleeping pill (sedative) zopiclone, over one month, on sleep apnoea severity, symptoms of daytime sleepiness, and measures of alertness in sleep apnoea patients

Interventions

Zopiclone (7.5mg) once a day immediately before going to bed, for 30 days. Taken orally. Adherence will be monitored via drug tablet return

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

Men and women with obstructive sleep apnoea (OSA)

Exclusion criteria

-People without OSA or who are currently on continuous positive airway pressure therapy for OSA -People with high arousal thresholds (average nadir epiglottic pressure just prior to arousal <-25cmH2O) as determined by overnight polysomnogram (sleep study) during a screening visit. -Known allergy or previous adverse reaction zopiclone -Pregnant or nursing mothers

Outcome results